# An Investigational Study of Continuous 8-Hour Intravenous Administrations of BMS-986231 in Participants With Heart Failure and Reduced Heart Function Given a Standard Dose of Loop Diuretic

> **NCT03730961** · PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 23 (actual)

## Conditions studied

- Cardiac Failure
- Myocardial Failure
- Congestive Heart Failure
- Heart Decompensation

## Interventions

- **DRUG:** BMS-986231
- **DRUG:** Furosemide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03730961
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-17
- **Primary completion:** 2019-12-11
- **Final completion:** 2020-01-09
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2021-02-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03730961

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03730961, "An Investigational Study of Continuous 8-Hour Intravenous Administrations of BMS-986231 in Participants With Heart Failure and Reduced Heart Function Given a Standard Dose of Loop Diuretic". Retrieved via MORVS 2026-11-03 from https://api.morvs.ai/clinical/NCT03730961. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*